These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

243 related articles for article (PubMed ID: 23570983)

  • 1. Just getting into cells is not enough: mechanisms underlying 4-(N)-stearoyl gemcitabine solid lipid nanoparticle's ability to overcome gemcitabine resistance caused by RRM1 overexpression.
    Wonganan P; Lansakara-P DS; Zhu S; Holzer M; Sandoval MA; Warthaka M; Cui Z
    J Control Release; 2013 Jul; 169(1-2):17-27. PubMed ID: 23570983
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The effect of the acid-sensitivity of 4-(N)-stearoyl gemcitabine-loaded micelles on drug resistance caused by RRM1 overexpression.
    Zhu S; Wonganan P; Lansakara-P DS; O'Mary HL; Li Y; Cui Z
    Biomaterials; 2013 Mar; 34(9):2327-39. PubMed ID: 23261218
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Stearoyl gemcitabine nanoparticles overcome resistance related to the over-expression of ribonucleotide reductase subunit M1.
    Chung WG; Sandoval MA; Sloat BR; Lansakara-P DS; Cui Z
    J Control Release; 2012 Jan; 157(1):132-40. PubMed ID: 21851843
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Oral 4-(
    Wang C; Zheng Y; Sand Oval MA; Valdes SA; Chen Z; Lansakara-P DS; Du M; Shi Y; Cui Z
    Oncotarget; 2017 Oct; 8(52):89876-89886. PubMed ID: 29163795
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Stearoyl gemcitabine nanoparticles overcome obesity-induced cancer cell resistance to gemcitabine in a mouse postmenopausal breast cancer model.
    De Angel RE; Blando JM; Hogan MG; Sandoval MA; Lansakara-P DS; Dunlap SM; Hursting SD; Cui Z
    Cancer Biol Ther; 2013 Apr; 14(4):357-64. PubMed ID: 23358472
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Synthesis and in vitro evaluation of novel lipophilic monophosphorylated gemcitabine derivatives and their nanoparticles.
    Lansakara-P DS; Rodriguez BL; Cui Z
    Int J Pharm; 2012 Jun; 429(1-2):123-34. PubMed ID: 22425885
    [TBL] [Abstract][Full Text] [Related]  

  • 7. EGFR-targeted stearoyl gemcitabine nanoparticles show enhanced anti-tumor activity.
    Sandoval MA; Sloat BR; Lansakara-P DS; Kumar A; Rodriguez BL; Kiguchi K; Digiovanni J; Cui Z
    J Control Release; 2012 Jan; 157(2):287-96. PubMed ID: 21871505
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Involvement of ribonucleotide reductase M1 subunit overexpression in gemcitabine resistance of human pancreatic cancer.
    Nakahira S; Nakamori S; Tsujie M; Takahashi Y; Okami J; Yoshioka S; Yamasaki M; Marubashi S; Takemasa I; Miyamoto A; Takeda Y; Nagano H; Dono K; Umeshita K; Sakon M; Monden M
    Int J Cancer; 2007 Mar; 120(6):1355-63. PubMed ID: 17131328
    [TBL] [Abstract][Full Text] [Related]  

  • 9. An increase in the expression of ribonucleotide reductase large subunit 1 is associated with gemcitabine resistance in non-small cell lung cancer cell lines.
    Davidson JD; Ma L; Flagella M; Geeganage S; Gelbert LM; Slapak CA
    Cancer Res; 2004 Jun; 64(11):3761-6. PubMed ID: 15172981
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Potent effect of adenoviral vector expressing short hairpin RNA targeting ribonucleotide reductase large subunit M1 on cell viability and chemotherapeutic sensitivity to gemcitabine in non-small cell lung cancer cells.
    Tokunaga Y; Liu D; Nakano J; Zhang X; Nii K; Go T; Huang CL; Yokomise H
    Eur J Cancer; 2015 Nov; 51(16):2480-9. PubMed ID: 26254808
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ribonucleotide reductase is an effective target to overcome gemcitabine resistance in gemcitabine-resistant pancreatic cancer cells with dual resistant factors.
    Minami K; Shinsato Y; Yamamoto M; Takahashi H; Zhang S; Nishizawa Y; Tabata S; Ikeda R; Kawahara K; Tsujikawa K; Chijiiwa K; Yamada K; Akiyama S; Pérez-Torras S; Pastor-Anglada M; Furukawa T; Yasuo T
    J Pharmacol Sci; 2015 Mar; 127(3):319-25. PubMed ID: 25837929
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Preparation, optimization and in vitro characterization of stearoyl-gemcitabine polymeric micelles: a comparison with its self-assembled nanoparticles.
    Daman Z; Ostad S; Amini M; Gilani K
    Int J Pharm; 2014 Jul; 468(1-2):142-51. PubMed ID: 24731731
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Lysosomal delivery of a lipophilic gemcitabine prodrug using novel acid-sensitive micelles improved its antitumor activity.
    Zhu S; Lansakara-P DS; Li X; Cui Z
    Bioconjug Chem; 2012 May; 23(5):966-80. PubMed ID: 22471294
    [TBL] [Abstract][Full Text] [Related]  

  • 14. In vivo induction of resistance to gemcitabine results in increased expression of ribonucleotide reductase subunit M1 as the major determinant.
    Bergman AM; Eijk PP; Ruiz van Haperen VW; Smid K; Veerman G; Hubeek I; van den Ijssel P; Ylstra B; Peters GJ
    Cancer Res; 2005 Oct; 65(20):9510-6. PubMed ID: 16230416
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Silencing of ribonucleotide reductase subunit M1 potentiates the antitumor activity of gemcitabine in resistant cancer cells.
    Wonganan P; Chung WG; Zhu S; Kiguchi K; Digiovanni J; Cui Z
    Cancer Biol Ther; 2012 Aug; 13(10):908-14. PubMed ID: 22785206
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Overcoming tumor cell chemoresistance using nanoparticles: lysosomes are beneficial for (stearoyl) gemcitabine-incorporated solid lipid nanoparticles.
    Chen Z; Zheng Y; Shi Y; Cui Z
    Int J Nanomedicine; 2018; 13():319-336. PubMed ID: 29391792
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Augmented delivery of gemcitabine in lung cancer cells exploring mannose anchored solid lipid nanoparticles.
    Soni N; Soni N; Pandey H; Maheshwari R; Kesharwani P; Tekade RK
    J Colloid Interface Sci; 2016 Nov; 481():107-16. PubMed ID: 27459173
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Just getting into cells is not enough.
    Park K
    J Control Release; 2013 Jul; 169(1-2):162. PubMed ID: 23763953
    [No Abstract]   [Full Text] [Related]  

  • 19. Efficient overcoming of drug resistance to anticancer nucleoside analogs by nanodelivery of active phosphorylated drugs.
    Galmarini CM; Warren G; Senanayake MT; Vinogradov SV
    Int J Pharm; 2010 Aug; 395(1-2):281-9. PubMed ID: 20580798
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ribonucleotide reductase M1 (RRM1) 2464G>A polymorphism shows an association with gemcitabine chemosensitivity in cancer cell lines.
    Kwon WS; Rha SY; Choi YH; Lee JO; Park KH; Jung JJ; Kim TS; Jeung HC; Chung HC
    Pharmacogenet Genomics; 2006 Jun; 16(6):429-38. PubMed ID: 16708051
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.